98%
921
2 minutes
20
Objectives: We sought to estimate the association between chronic use of renin-angiotensin system inhibitors and acute kidney injury requiring renal replacement therapy in critically ill adult patients with sepsis.
Design: Population-based cohort study in Ontario, Canada.
Setting: ICUs in Ontario, Canada, between April 2008 and March 2019.
Patients: Elderly patients admitted to an ICU with a sepsis diagnosis; we excluded patients with established indications of renin-angiotensin system inhibitors.
Interventions: The prior use (i.e., within 100 d of hospitalization) of an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker served as the main exposure of interest; the active comparator was the prior use of calcium channel blockers.
Measurements And Main Results: Acute kidney injury requiring renal replacement therapy was the primary outcome. Septic shock and all-cause mortality at 30 days served as secondary outcomes. We fitted multivariable modified Poisson regression models to adjust for potential confounders; associations were reported as risk ratios (RRs) alongside 95% CIs. We included 8621 patients, of whom 81% received a renin-angiotensin system inhibitor; mean age was 78 years. Renal replacement therapy was performed in 3.2% of patients; compared with the prior use of a calcium channel blocker, prior use of a renin-angiotensin system inhibitor was associated with a higher risk of acute kidney injury and renal replacement therapy (RR, 1.57; 95% CI, 1.10-2.24), septic shock (RR, 1.18; 95% CI, 1.04-1.33), but not all-cause mortality at 30 days (RR, 0.93; 95% CI, 0.88-1.01). Our results were robust across sensitivity analyses.
Conclusions: Chronic use of a renin-angiotensin system inhibitor is associated with a higher risk of renal replacement therapy and septic shock in adult patients with sepsis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12384932 | PMC |
http://dx.doi.org/10.1097/CCE.0000000000001304 | DOI Listing |
J Prim Care Community Health
September 2025
Division of Nephrology, Department of Medicine, National University Hospital, Singapore.
Background: Chronic kidney disease (CKD) management was largely centered around renin-angiotensin-aldosterone system inhibitors (RAASi) optimization, until recent emergence of novel therapeutics. However, slow adoption of guideline-directed therapy leaves patients vulnerable to disease progression. In 2022, a data-driven informatics approach was introduced to track real-time adherence to best practices.
View Article and Find Full Text PDFDiabetes Metab Res Rev
September 2025
Department of Nephrology, Daping Hospital, Army Medical University, Chongqing, China.
Chronic kidney disease (CKD) substantially increases cardiovascular risk, with endothelial dysfunction as its central pathological mechanism. This review summarises the molecular regulatory mechanisms underlying endothelial dysfunction in CKD and highlights recent advances in treatment strategies. The pathophysiology of endothelial injuries involves a complex network of multiple factors and mechanisms, including oxidative stress, inflammation, glycocalyx damage, ischaemia, hypoxia, cellular senescence and endothelial-mesenchymal transition (EndMT).
View Article and Find Full Text PDFMod Rheumatol Case Rep
September 2025
Department of Rheumatology, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura-shi, Kanagawa, 247-8533, Japan.
A 46-year-old man was diagnosed with anti jo-1 antibody-positive dermatomyositis 11 years ago and had been treated with prednisolone and tacrolimus. In the present case, after contracting SARS CoV2 virus infection, his dyspnea rapidly worsened, and he presented with renal and cardiac failure. Based on the biopsy results of the same area and anti-U1-RNP antibody positivity, he was diagnosed with systemic sclerosis and scleroderma renal crisis and required hemodialysis.
View Article and Find Full Text PDFLife Sci
September 2025
Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan, 333031, India. Electronic address:
Cardiorenal syndrome (CRS) is a bidirectional relationship shared between the heart and kidneys, both in physiological and pathophysiological perspectives. The metabolic, hemodynamic, and neurohormonal alterations between the heart and kidneys drive this dual-organ damage and are responsible for one of the highest medical concerns around the globe. From a pathophysiological perspective, activation of the renin-angiotensin system, persistent inflammation, oxidative stress, and reactive fibrosis are accountable for the damage to the heart and kidneys.
View Article and Find Full Text PDFInt Urol Nephrol
September 2025
National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Xuanwu District, No. 305 East Zhongshan Road, Nanjing, 210016, Jiangsu, China.
Purpose: To evaluate the short-term efficacy and safety of finerenone in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD).
Methods: A retrospective cohort study was conducted on a relatively small sample of 23 patients diagnosed with T1D and CKD between January 2023 and August 2024. All patients received renin-angiotensin system inhibitors (RASi), with 12 patients additionally treated with finerenone.